No Data
No Data
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis
AbbVie said the U.S. Food and Drug Administration approved Skyrizi for adults diagnosed with moderately to severely active ulcerative colitis.
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
USA News Group – This year's 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without...
Why AbbVie (ABBV) Is a Great Dividend Stock Right Now
Here's Why AbbVie (ABBV) Is a Strong Momentum Stock
AbbVie's SKYRIZI Gains US FDA Approval for Ulcerative Colitis
ABBV.US's heavyweight IL-23 inhibitor has once again been approved by the FDA for the treatment of ulcerative colitis.
AbbVie (ABBV.US) announced that the FDA has approved its IL-23 inhibitor, Risankizumab, for the treatment of adult patients with moderate to severe active ulcerative colitis.
No Data